Loading filters...
Publications per Year (1046 total)
31
1990
29
·
44
·
31
·
32
·
26
1995
29
·
35
·
21
·
40
·
42
2000
36
·
45
·
52
·
63
·
42
2005
7
·
12
·
15
·
15
·
11
2010
21
·
16
·
22
·
20
·
18
2015
24
·
22
·
28
·
30
·
23
2020
28
·
28
·
27
·
30
·
22
2025
29
·
Loaded
Click to load
50 / 1046 papers loaded(scroll for more)
202629 papers
GeneralAll Stages2026
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.
Xu W et al. Eur Urol. 2026
TKIAll Stages2026
Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma.
Wang J et al. Cancer Res. 2026
First-line IOAdvanced/Metastatic2026
Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma.
Tsimafeyeu I et al. Urol Oncol. 2026
First-line IOAdvanced/Metastatic2026
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.
Porcari S et al. Nat Med. 2026
TKIAdvanced/Metastatic2026
Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study.
Shah NJ et al. Urol Oncol. 2026
GeneralAdvanced/Metastatic2026
Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study.
Rioja P et al. Urol Oncol. 2026
GeneralAdvanced/Metastatic2026
Oligoprogressive renal cell carcinoma: What is the role of surgery?
Re C et al. BJU Int. 2026
GeneralAll Stages2026
Evaluation of algorithms for predicting new baseline renal function after complex partial nephrectomy for multifocal renal tumors.
Rathi N et al. Urol Oncol. 2026
TKIAdvanced/Metastatic2026
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.
Alves Costa Silva C et al. Nat Med. 2026
GeneralAll Stages2026
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy.
Lazarovich A et al. J Urol. 2026
cytokineAdvanced/Metastatic2026
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.
Lassen U et al. ESMO Open. 2026
GeneralAdvanced/Metastatic2026
Laboratory paraneoplastic syndrome resolution is associated with reduced recurrence and improved survival in non-metastatic renal cell carcinoma.
Lahiji R et al. Urol Oncol. 2026
GeneralAll Stages2026
Impact of intraoperative intravenous heparin bolus on clinical outcomes during radical nephrectomy and IVC tumor thrombectomy in renal cell carcinoma with level I-IV IVC thrombus: A multi-institutional study.
Aydin AM et al. Urol Oncol. 2026
First-line IOAdvanced/Metastatic2026
An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma.
Ishiyama Y et al. Urol Oncol. 2026
First-line IOAdvanced/Metastatic2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.
Motzer RJ et al. Ann Oncol. 2026
First-line IOAdvanced/Metastatic2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Choueiri TK et al. Ann Oncol. 2026
First-line IOAdvanced/Metastatic2026
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
Motzer RJ et al. Ann Oncol. 2026
TKIAdvanced/Metastatic2026
Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
Negrier S et al. Eur J Cancer. 2026
First-line IOAdvanced/Metastatic2026
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.
Suarez C et al. Ann Oncol. 2026
TKIearly2026
HIF-2α Inhibitor Combinations Knock Back Kidney Cancer in Two Trials.
Cancer Discov. 2026
TKIAdvanced/Metastatic2026
First-line sunitinib for metastatic renal cell carcinoma, a 15-year single institution real-world evidence study.
Haman M et al. Urol Oncol. 2026
GeneralAdvanced/Metastatic2026
Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future?
Flammia RS et al. BJU Int. 2026
GeneralAll Stages2026
sPaRT2 - Minimally Invasive Partial versus Radical Nephrectomy for cT2 Renal Cell Carcinoma: A National Matched-Pair Analysis (UroCCR 235).
Et-Touzani R et al. J Urol. 2026
First-line IOAdvanced/Metastatic2026
Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study.
Cigliola A et al. ESMO Open. 2026
GeneralAll Stages2026
Venous invasion in upper tract urothelial carcinoma: Diagnostic features and oncologic outcomes.
Brönimann S et al. Urol Oncol. 2026
First-line IOAdvanced/Metastatic2026
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.
Blanchet B et al. Br J Cancer. 2026
GeneralAdvanced/Metastatic2026
Comparison of partial nephrectomy to radical nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian Multi-Institutional Collaborative.
Bansal RK et al. Urol Oncol. 2026
GeneralAll Stages2026
Redo partial or radical nephrectomy for solitary renal recurrence after previous nephron-sparing surgery: Is functional preservation always justified?
Anceschi U et al. Urol Oncol. 2026
First-line IOAdvanced/Metastatic2026
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma.
Albiges L et al. Eur Urol. 2026
202521 papers
HIF-2αAdvanced/Metastatic2025
Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel-Lindau (VHL) disease-associated haemangioblastoma.
Shepherd STC et al. ESMO Open. 2025
TKIAdvanced/Metastatic2025
De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma.
Teisseire M et al. Cancer Res. 2025
Generalearly2025
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions.
Marandino L et al. Eur Urol Oncol. 2025
HIF-2αAdvanced/Metastatic2025
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
Powles T et al. Lancet Oncol. 2025
HIF-2αAdvanced/Metastatic2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.
Srinivasan R et al. Lancet Oncol. 2025
TKIAdvanced/Metastatic2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Choueiri TK et al. Lancet Oncol. 2025
First-line IOAdvanced/Metastatic2025
Activity of lenvatinib-based therapy in previously treated patients with metastatic renal cell carcinoma: A European multicenter study (LENVA-LAT).
Gavira J et al. Eur J Cancer. 2025
TKIAdvanced/Metastatic2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma.
Kotecha RR et al. Eur Urol Oncol. 2025
First-line IOAdvanced/Metastatic2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.
Voss MH et al. Eur Urol. 2025
First-line IOAdvanced/Metastatic2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.
Rini BI et al. Nat Med. 2025
First-line IOAdvanced/Metastatic2025
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma.
Ishihara H et al. Urol Oncol. 2025
First-line IOAdvanced/Metastatic2025
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
Motzer RJ et al. Ann Oncol. 2025
First-line IOAdvanced/Metastatic2025
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
Choueiri TK et al. Ann Oncol. 2025
First-line IOAdvanced/Metastatic2025
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.
Gouda MA et al. ESMO Open. 2025
HIF-2αAll Stages2025
HIF-2-Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell Carcinoma.
Mal A et al. Cancer Discov. 2025
First-line IOAdvanced/Metastatic2025
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis.
Gupta M et al. Eur Urol Oncol. 2025
GeneralAll Stages2025
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study.
Grünwald V et al. Eur J Cancer. 2025
First-line IOAdvanced/Metastatic2025
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial.
Gao B et al. JAMA Oncol. 2025
TKIAdvanced/Metastatic2025
Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors.
Khaleel S et al. Urol Oncol. 2025
First-line IOAdvanced/Metastatic2025
Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER study.
Cella D et al. ESMO Open. 2025
GeneralAll Stages2025
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma.
Bedke J et al. Eur Urol. 2025